Paliperidone palmitate (Invega Trinza®) is an extended-release injectable second-generation (“atypical”) antipsychotic which can be administered once every 3 months. Here is basic information about this medication.

FDA-Approved Indication

Schizophrenia after adequate treatment with 1-month paliperidone palmitate extended-release (Invega Sustenna®) for at least four months.

Dosage

The dose of 3-month paliperidone palmitate (Invega Trinza®) will depend on the last dose of 1-month paliperidone palmitate extended-release (Invega Sustenna) that the patient was on, as follows:

 

Last dose of 1-month paliperidone palmitate	Starting dose of 3-month paliperidone palmitate
78 mg	273 mg
117 mg	410 mg
156 mg	546 mg
234 mg	819 mg

Dosage forms and strengths

Extended-release injectable suspension: 273 mg, 410 mg, 546 mg, 819 mg

Prescribing Information

It is extremely important that prescriber’s review the full prescribing information before prescribing 3-month paliperidone palmitate (Invega Trinza)